FDA
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Humanigen Reports Year-End 2021 Financial Results
-
-
-
-
-
-
-
Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe
-
-
-
-
-
-
-
Humanigen Inc. (HGEN) Says Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
-
-
-
-
-
-
-
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)
-
-
-
-
-
-
-
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

